Jin Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7497652/publications.pdf

Version: 2024-02-01

78 papers	2,255 citations	411340 20 h-index	252626 46 g-index
79 all docs	79 docs citations	79 times ranked	4567 citing authors

#	Article	IF	Citations
1	Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. Annals of Pharmacotherapy, 2022, 56, 222-223.	0.9	0
2	Voxelotor and albuminuria in adults with sickle cell anaemia. British Journal of Haematology, 2022, , .	1.2	5
3	Evaluation of pointâ€ofâ€care International Normalized Ratio in sickle cell disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12533.	1.0	0
4	Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. British Journal of Haematology, 2021, 194, 767-778.	1.2	6
5	Effects of reninâ€angiotensin blockade and APOL1 on kidney function in sickle cell disease. EJHaem, 2021, 2, 483-484.	0.4	2
6	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. JAMA Network Open, 2021, 4, e2118410.	2.8	1
7	Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer. Phytomedicine, 2021, 91, 153674.	2.3	13
8	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12â€year single health systemâ€based cohort analysis. EJHaem, 2021, 2, 97-101.	0.4	0
9	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Advances, 2021, 5, 207-215.	2.5	59
10	Genotype-Guided vs Clinically-Guided Stable Warfarin Dose Prediction and Stable Dose Establishment In A Predominantly Non-European Ancestry Population. Expert Review of Precision Medicine and Drug Development, 2021, 6, 375-379.	0.4	0
11	Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. Haematologica, 2021, 106, 1745-1748.	1.7	3
12	Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. Blood, 2021, 138, 2051-2051.	0.6	1
13	Defining and Predicting Rapid Egfr Decline in Sickle Cell Disease. Blood, 2021, 138, 122-122.	0.6	1
14	Clinical and Biomarker Predictors for Avascular Necrosis in Sickle Cell Disease. Blood, 2021, 138, 3091-3091.	0.6	0
15	HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. Blood, 2021, 138, 950-950.	0.6	0
16	Naloxone Use for Opioid Reversal in Patients with Sickle Cell Disease. Blood, 2021, 138, 2038-2038.	0.6	0
17	Haptoglobin 1-1 Isoform Predicts Higher Serum Haptoglobin Concentration and Lower Multiorgan Failure Risk in Sickle Cell Disease. Blood, 2021, 138, 3095-3095.	0.6	0
18	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. Journal of Cancer Survivorship, 2020, 14, 294-304.	1.5	9

#	Article	IF	Citations
19	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. British Journal of Haematology, 2020, 191, e70-e72.	1.2	3
20	Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Advances, 2020, 4, 1978-1986.	2.5	28
21	Systematic Review of Voxelotor: A Firstâ€inâ€Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. Pharmacotherapy, 2020, 40, 525-534.	1.2	17
22	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vasoâ€occlusive Pain Crises in Patients with Sickle Cell Disease. Pharmacotherapy, 2020, 40, 535-543.	1.2	19
23	COVIDâ€19 infection in patients with sickle cell disease. British Journal of Haematology, 2020, 189, 851-852.	1.2	90
24	Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. Blood, 2020, 136, 21-22.	0.6	0
25	Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center. Blood, 2020, 136, 22-23.	0.6	1
26	Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. Blood, 2020, 136, 18-19.	0.6	0
27	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. Blood, 2020, 136, 34-35.	0.6	0
28	Kidney ultrasound findings according to kidney function in sickle cell anemia. American Journal of Hematology, 2019, 94, E288-E291.	2.0	4
29	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner etÂal. British Journal of Haematology, 2019, 186, 782-783.	1.2	0
30	â€œMaximum tolerated doseâ€•vs â€œfixed lowâ€•doseâ€•hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 2019, 94, E112-E115.	2.0	7
31	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6â€Year Propensity Scoreâ€“Matched Cohort Study. Pharmacotherapy, 2019, 39, 55-66.	1.2	8
32	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. Obesity Surgery, 2019, 29, 3762-3764.	1.1	0
33	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a sixâ€year populationâ€based cohort analysis. British Journal of Haematology, 2019, 185, 116-127.	1.2	14
34	The morbidity and mortality of end stage renal disease in sickle cell disease. American Journal of Hematology, 2019, 94, E138-E141.	2.0	11
35	Use of metformin in patients with sickle cell disease. American Journal of Hematology, 2019, 94, E13-E15.	2.0	5
36	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. American Journal of Hematology, 2019, 94, E5-E7.	2.0	1

#	Article	IF	Citations
37	Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. Blood, 2019, 134, 3558-3558.	0.6	2
38	Risk Factors for Kidney Disease in Hb SC and Hb SÎ²+-Thalassemia Sickle Cell Disease. Blood, 2019, 134, 2299-2299.	0.6	0
39	Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. Blood, 2019, 134, 3390-3390.	0.6	0
40	Implementation of a Standard Order Set at a Sickle Cell Acute Care Observation Unit. Blood, 2019, 134, 3396-3396.	0.6	0
41	Program expansion of a day hospital dedicated to manage sickle cell pain. American Journal of Hematology, 2018, 93, E20-E21.	2.0	7
42	Erythropoiesisâ€stimulating agents in sickle cell anaemia. British Journal of Haematology, 2018, 182, 602-605.	1.2	9
43	Characterization of opioid use in sickle cell disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 479-486.	0.9	37
44	HMOX1 and acute kidney injury in sickle cell anemia. Blood, 2018, 132, 1621-1625.	0.6	20
45	Risk factors for vitamin D deficiency in sickle cell disease. British Journal of Haematology, 2018, 181, 828-835.	1.2	16
46	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6â€year populationâ€based cohort study. British Journal of Haematology, 2018, 182, 259-270.	1.2	16
47	Hemolysis and hemolysisâ€related complications in females vs. males with sickle cell disease. American Journal of Hematology, 2018, 93, E376-E380.	2.0	14
48	Reply to <scp>R</scp>uan <scp>X</scp> et al: â€œA comment on pattern of opioid use in sickle cell diseaseâ€. American Journal of Hematology, 2017, 92, E43.	2.0	1
49	APOL1 , Î±-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica, 2017, 102, e1-e6.	1.7	47
50	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. Haematologica, 2017, 102, e282-e284.	1.7	4
51	Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease. Annals of Pharmacotherapy, 2017, 51, 357-358.	0.9	15
52	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb SÎ²+â€thalassemia sickle cell disease. American Journal of Hematology, 2016, 91, E316-7.	2.0	1
53	Patterns of opioid use in sickle cell disease. American Journal of Hematology, 2016, 91, 1102-1106.	2.0	24
54	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. Pharmacotherapy, 2016, 36, 1166-1172.	1.2	10

#	Article	IF	Citations
55	Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. American Journal of Health-System Pharmacy, 2016, 73, 947-948.	0.5	8
56	Platelets decline during <scp>V</scp>asoâ€occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. American Journal of Hematology, 2015, 90, E228-9.	2.0	12
57	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. Pharmacotherapy, 2015, 35, 696-700.	1.2	7
58	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Human Genetics, 2015, 134, 895-904.	1.8	20
59	Mitochondria as therapeutic targets for cancer stem cells. World Journal of Stem Cells, 2015, 7, 418.	1.3	48
60	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. Blood, 2015, 126, 3400-3400.	0.6	3
61	Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. Blood, 2015, 126, 3413-3413.	0.6	0
62	Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths. International Journal of Pharmaceutics, 2014, 473, 375-383.	2.6	34
63	Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. Biochemical Pharmacology, 2014, 88, 150-157.	2.0	60
64	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1469-1475.	1.4	10
65	Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure. PLoS ONE, 2013, 8, e71268.	1.1	14
66	Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage. Molecular Cancer Therapeutics, 2012, 11, 2311-2320.	1.9	16
67	The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nature Immunology, 2012, 13, 29-34.	7.0	195
68	Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. Journal of Experimental Medicine, 2009, 206, 707-719.	4.2	81
69	Intrathymic proliferation wave essential for VÎ±14 ⁺ natural killer T cell development depends on c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8641-8646.	3.3	100
70	The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage. Immunity, 2008, 29, 391-403.	6.6	637
71	Actin-Binding Protein 1 Regulates B Cell Receptor-Mediated Antigen Processing and Presentation in Response to B Cell Receptor Activation. Journal of Immunology, 2008, 180, 6685-6695.	0.4	51
72	Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cellâ€“mediated immune responses. Nature Immunology, 2007, 8, 84-91.	7.0	156

#	Article	IF	Citations
73	HIP-55 Is Important for T-Cell Proliferation, Cytokine Production, and Immune Responses. Molecular and Cellular Biology, 2005, 25, 6869-6878.	1.1	56
74	Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Research, 2005, 33, 2769-2780.	6.5	41
75	ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Research, 2004, 32, 1232-1241.	6.5	38
76	The SH3 Domain-containing Adaptor HIP-55 Mediates c-Jun N-terminal Kinase Activation in T Cell Receptor Signaling. Journal of Biological Chemistry, 2003, 278, 52195-52202.	1.6	51
77	Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase. Journal of Biological Chemistry, 2002, 277, 39334-39342.	1.6	81
78	Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children. Pakistan Journal of Medical Sciences, 1969, 30, 519-24.	0.3	3